- The All India Institute of Medical Sciences (AIIMS) is starting its human clinical trial of the indigenously-developed COVID-19 vaccine COVAXIN from today.
- AIIMS Ethics Committee has given its nod for the human clinical trial of COVAXIN.
- AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research(ICMR) for conducting phase I and II human trials of COVAXIN.